Dana-Farber has elected the largest cohort of physician-investigators to the 2025 class of ASCI
Dana-Farber Cancer Institute shared a post on LinkedIn
“Dana-Farber has elected the largest cohort of physician-investigators to the 2025 class of American Society for Clinical Investigation (ASCI).
Out of the 99 medical institutions across disciplines with physicians who earned ASCI membership, our eight faculty members represented the largest cohort.
‘This speaks to the quality of protection of, and support for, physician-scientists at Dana-Farber,’ says pediatric neuro-oncologist and member of the 2025 ASCI group, Pratiti (Mimi) Bandopadhayay, MBBS, PhD.
Her widely published research is focused on using cancer genomics to identify new therapeutic targets in brain tumors and to characterize the mechanisms of resistance to cancer therapies.
She is joined in this class by a pediatric neuro-oncology colleague, Mariella Filbin, MD, PhD. Filbin’s award-winning work identifies the ways in which normal cells turn cancerous, yet retain latent developmental potential, which can be used for establishing new targets for treatments.
Another pediatric oncologist, Robbie Majzner, MD, is focused on developing and testing new immunotherapies. Majzner understands the potential of physician-researcher discoveries to translate to effective treatments for previously incurable cancers.
Treating adults with pancreatic cancer, radiation oncologist Joseph Mancias, MD, PhD, sees another side of the cancer spectrum. Mancias studies the role of the body’s process of reusing old and damaged cell parts (autophagy), iron metabolism, and therapeutic resistance in pancreatic ductal adenocarcinoma.
In the Lowe Center for Thoracic Oncology, Matthew Oser, MD, PhD, is focused on uncovering the underlying mechanisms of rare and fast-growing small cell lung cancers. It’s only fitting that he is part of this ASCI cohort since he joined Dana-Farber as a postdoctoral researcher in Kaelin’s lab.
The work of Abby Rosenberg, MD, MS, MA, FAAP, FAAHPM, is focused on promoting resilience and quality of life for children, adolescents, and young adults with serious illness. As Chief of Pediatric Palliative Care and an expert in her field, Rosenberg has published more than 250 peer-reviewed studies and led the development of programming that furthers the well-being of people with cancer and their families.
Nilay Sethi, MD, PhD, is a medical oncologist who treats patients with gastrointestinal cancers. He is also a renowned investigator widely recognized for his work uncovering how genes and the environment work together and potentially lead to early stages of gastrointestinal cancers.
He is joined by a fellow medical oncologist in the Lank Center for Genitourinary Oncology, Srinivas Viswanathan, MD, PhD. In his lab, Viswanathan uses advanced genomic and genetic tools to uncover the molecular mechanisms that drive genitourinary cancers and expose their weaknesses.
These eight physician-investigators have already made celebrated discoveries that are impacting how cancer is understood and how patients are treated.”
More posts featuring Dana-Farber Cancer Institute.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023